By leveraging the power of our proprietary, artificial intelligence-based drug discovery platform, CHEMSAS®, we are positioned to improve the drug discovery process and build the pipeline of large pharmaceutical companies more efficiently. The CHEMSAS® platform is a computational replication of the traditional “wet lab” drug discovery process. The difference is that failed attempts to hit therapeutic targets occur in computer simulations as opposed to incurring the high costs of synthesis and testing at the “research bench”. CHEMSAS® substantially reduces the cost and time of identifying drug candidates at the discovery stage of drug development.
By in-licensing our novel, optimized lead compounds, our partners can augment their pipelines in a highly targeted fashion, potentially extend patent life by several years and reduce the immense cost of their traditional drug discovery process by up to $200 million per successful drug.
Artificial intelligence-based technology yielding positive results in drug discovery collaborations
Xconomy | Constructing innovation supply chains for the pharmaceutical industry